Star Combo Pharma reported a 23% decline in revenue to $11.9 million for the half year ended December 2025, driven by the loss of a major OEM contract and closure of its AustoYou retail business. Despite this, operating profit after tax rose 49% to $413,243, reflecting effective cost management.
